N-ethyl-N-methyl isonicotinamide | 1155821-82-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-ethyl-N-methyl isonicotinamide
• 英文别名: N-ethyl-N-methylpyridine-4-carboxamide
• CAS: 1155821-82-1
• 化学式: C₉H₁₂N₂O
• 分子量: 164.207
• InChiKey: OUFZLFXPIHTNTI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  33.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  氯化异氰盐酸盐 、 N-methylethylamine hydroiodide 在 吡啶 作用下， 反应 3.0h， 以13.0 mg的产率得到N-ethyl-N-methyl isonicotinamide
  参考文献：
  名称：

  Yebeutchou, Roger M.; Dalcanale, Enrico, Journal of the American Chemical Society, 2009, vol. 131, p. 2452 - 2453

  摘要：

  DOI：

文献信息

• METHODS FOR INHIBITING DRUG DEGRADATION
  申请人：SEQUOIA PHARMACEUTICALS, INC.

  公开号：US20150284352A1

  公开（公告）日：2015-10-08

  Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.

  提供了一种抑制细胞色素P450酶的方法，可用于改善疾病治疗，防止药物或其他分子被细胞色素P450降解。提供了可以充当增强剂的药物组合物，以改善药物的药代动力学，增加生物利用度，并增强那些在体内被细胞色素P450酶降解的药物的治疗效果。
• Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists
  申请人：Gendron Roland

  公开号：US20060276482A1

  公开（公告）日：2006-12-07

  The invention provides novel benzoimidazolone-carboxamide 5-HT 4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT 4 receptor activity, and processes and intermediates useful for preparing such compounds.

  这项发明提供了新型苯并咪唑酮-羧酰胺5-HT4受体激动剂化合物。该发明还提供了包含这些化合物的药物组合物，使用这些化合物来治疗与5-HT4受体活性相关的疾病的方法，以及用于制备这些化合物的过程和中间体。
• [EN] FUNCTIONALIZED AND MULTIVARIATE BTB-BASED METAL ORGANIC FRAMEWORKS<br/>[FR] STRUCTURES DE SQUELETTES ORGANOMÉTALLIQUES À BASE DE BTB À PLUSIEURS VARIABLES ET FONCTIONNALISÉS
  申请人：UNIV CALIFORNIA

  公开号：WO2015157239A1

  公开（公告）日：2015-10-15

  The disclosure provides for metal organic frameworks (MOFs) which comprise a plurality of SBUs linked together by functionalized or multivariate BTB-based linking ligands. The disclosure further provides for the use of these MOFs in variety of applications, including for gas separation, gas storage, catalysis, and separation of compounds or bioproducts.

  该披露提供了一种金属有机框架（MOFs），其包括通过功能化或多元BTB基连接配体连接在一起的多个SBUs。该披露进一步提供了这些MOFs在各种应用中的使用，包括用于气体分离、气体储存、催化和化合物或生物产品的分离。
• Benzoimidazolone-carboxamide compounds as 5-HT4 receptor agonists
  申请人：Gendron Roland

  公开号：US20080070923A1

  公开（公告）日：2008-03-20

  The invention provides novel benzoimidazolone-carboxamide 5-HT 4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT 4 receptor activity, and processes and intermediates useful for preparing such compounds.

  本发明提供了新型苯并咪唑酮-羧酰胺5-HT4受体激动剂化合物。本发明还提供了包含这些化合物的药物组合物，使用这些化合物治疗与5-HT4受体活性相关的疾病的方法，以及用于制备这些化合物的过程和中间体。
• COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450
  申请人：Eissenstat Michael

  公开号：US20080113945A1

  公开（公告）日：2008-05-15

  Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.